Fiche centre
Novartis Investigative Site
Berlin — Germany
Essais liés8clinical trials
VilleBerlinlocalisation
PaysGermanylocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT05268289
Essais cliniques associés
8| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Ribociclib | Cancer | Phase 3 | NCT05827081 | Adjuvant WIDER — Phase IIIb Study of Ribociclib + ET in Early Breast Cancer | RECRUITING |
| AIOLOS — A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis | SEP | À vérifier | NCT05344469 | AIOLOS — A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis | RECRUITING |
| VHB937 | Sclérose latérale amyotrophique | Phase 2 | NCT06643481 | ASTRALS — A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS) | ACTIVE_NOT_RECRUITING |
| Iptacopan (part 1) | Lupus | Phase 2 | NCT05268289 | Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V | RECRUITING |
| Erenumab | Migraine | Phase 4 | NCT04084314 | APOLLON — Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study | COMPLETED |
| Nilotinib followed by treatment-free | Cancer | Phase 2 | NCT01784068 | ENESTfreedom — Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients | COMPLETED |
| Remibrutinib oral treatment | SEP | Phase 3 | NCT06846281 | Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. | RECRUITING |
| RAD001 | Épilepsie | Phase 3 | NCT01713946 | A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures | COMPLETED |